This Underperforming Biotech Is Ready to Beat the Market
Despite growing by more than 600% over the past 10 years (more than doubling the S&P 500's returns in the process), over the past five years, biopharmaceutical company Incyte (NASDAQ: INCY) has barely budged. In that time, the company's shares are up approximately 10%. Not annually. Not year-to-date. Not within the week. That's 10% total over the entire past five years. This lags the S&P 500 and its 90%-ish growth over that time, and it lags the Nasdaq Biotech ETF (NASDAQ: IBB) and its 70%.
Fortunately, Incyte may soon be able to squeeze more juice from its crown jewel.
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com
